A naukri.com initiative
Baystreet
1w
119
Image Credit: Baystreet
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain
- Traditional research institutions facing budget constraints are pushing the burden of advancing cancer treatment onto private enterprises like biotech firms.
- Investor attention is shifting towards biotech companies like Oncolytics Biotech Inc., NovoCure Limited, Nuvation Bio Inc., Guardant Health, Inc., and SELLAS Life Sciences Group, Inc.
- Analysts foresee significant growth in oncology markets, with immunotherapy projected to reach a global market value of US$1.2 trillion by 2033.
- Oncolytics Biotech Inc. is gaining visibility for its upcoming presentation at the 2025 ASCO Annual Meeting, showcasing new clinical trial data on pelareorep's immunological activity in pancreatic cancer.
- Pelareorep shows promise in converting 'cold' tumors into 'hot,' inflamed environments, potentially enhancing vulnerability to immune attack in pancreatic cancer.
- The abstract detailing the role of pelareorep in activating anti-tumor immunity in pancreatic ductal adenocarcinoma will be presented at the upcoming conference.
- Oncolytics' GOBLET study has shown promising results with pelareorep in combination with various therapies, producing positive outcomes in pancreatic cancer and other cancer types.
- Pelareorep's adaptability with different chemotherapies and checkpoint inhibitors, along with its favorable safety profile, positions it as a potential immune booster in diverse treatment regimens.
- Key opinion leaders support pelareorep's approach in turning cold tumors hot, crucial for making immunotherapies effective in traditionally resistant cancers.
- Oncolytics Biotech is well-positioned with scientific validation, clinical flexibility, and financial control, ending Q1 2025 with substantial cash reserves and financing support.
Read Full Article
7 Likes
For uninterrupted reading, download the app